Cargando…

Convalescent-anti-SARS-CoV-2-plasma/enoxaparin-sodium/methylprednisolone: Various toxicities and off label use: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501371/ http://dx.doi.org/10.1007/s40278-021-03360-1

Ejemplares similares

Enoxaparin sodium/methylprednisolone: Cytomegalovirus reactivation, gastrointestinal haemorrhage and off-label use: case report
Publicado: (2020)

Dexamethasone/enoxaparin-sodium/methylprednisolone: Occipital lobe haemorrhages and off-label use: case report
Publicado: (2021)

Remdesivir/methylprednisolone/convalescent-anti-SARS-CoV-2-plasma: Elevated aminotransferase levels and off-label use: case report
Publicado: (2021)

Enoxaparin sodium: Various toxicities: 3 case reports
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/tisagenlecleucel: Various toxicities: 2 case reports
Publicado: (2021)

Hydrocortisone/methylprednisolone/tocilizumab: Various toxicities following off-label treatment: case report
Publicado: (2021)

Dexamethasone/methylprednisolone: Various toxicities following off label use: 21 case reports
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Transfusion reaction during off-label therapy: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2022)

Methylprednisolone/tocilizumab: Various toxicities, off label use and lack of efficacy: 2 case reports
Publicado: (2022)

Enoxaparin sodium/mRNA-1273: Various toxicities: case report
Publicado: (2021)

Enoxaparin sodium/heparin/warfarin: Various toxicities: 3 case reports
Publicado: (2021)

Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2021)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/remdesivir: Treatment failure and off-label use: case report
Publicado: (2021)

Blinatumomab/convalescent-anti-SARS-CoV-2-plasma: B-cell depletion and off label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Antivirals/convalescent-anti-SARS-CoV-2-plasma/imatinib: Haematological disorder and off label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Febrile TACO reaction following off-label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/heparin: Lack of efficacy following an off-label treatment: case report
Publicado: (2022)

Enoxaparin sodium/prednisolone: Lack of efficacy and off label use: case report
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022)

Apixaban/dabigatran etexilate/enoxaparin sodium: Various toxicities: 8 case reports
Publicado: (2022)

Anakinra\Convalescent-anti-SARS-CoV-2-plasma\dexamethasone: Pulmonary Aspergillosis and off label use: 6 case reports
Publicado: (2021)

Azithromycin/convalescent-anti-SARS-CoV-2-plasma/steroids: Necrotising pancreatitis following off label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/immunosuppressants: SARS-CoV-2 infection, its re-infection and off label use: case report
Publicado: (2021)

Dexamethasone/enoxaparin-sodium/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022)

Convalescent-anti-sars-cov-2-plasma: Allergic urticaria and anaphylaxis following off label use: 2 case reports
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/remdesivir: Sinus bradycardia, elevated ALT and off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Transfusion-related acute lung injury following off-label use: case report
Publicado: (2021)

Anakinra/convalescent-anti-SARS-CoV-2-plasma/prednisolone: Aggravation of SARS-CoV-2 hepatitis, SARS-CoV-2 viraemia and off-label use: case report
Publicado: (2021)

Methylprednisolone: Worsening of SARS-CoV-2 infection during off-label treatment: case report
Publicado: (2020)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/favipiravir: Avascular necrosis of femoral head and off-label use: case report
Publicado: (2021)

Dexamethasone/enoxaparin-sodium/remdesivir: Lack of efficacy following off-label use: case report
Publicado: (2021)

Enoxaparin-sodium/favipiravir: Acute generalised exanthematous pustulosis and off-label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/voriconazole: Invasive pulmonary aspergillosis, off label use and lack of efficacy: case report
Publicado: (2021)

Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients
por: Soo, Y. O. Y., et al.
Publicado: (2004)

Convalescent-anti-sars-cov-2-plasma: Transfusion-related acute lung injury following off-label use: 2 case reports
Publicado: (2022)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximab: Depletion of B-lymphocytes, lack of efficacy and off label treatment: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0qdpv91gpukqn5k7dmem41mji